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Introduction. The symptom burden and role of palliative care (PC) in patients with advanced soft tissue sarcoma (STS) are not well
deﬁned. Methods. This study retrospectively reviewed both symptoms and PC involvement in patients known to an STS referral
centre who died in one calendar year. Results. 81 patients met inclusion criteria of which 27% had locally advanced disease and
73% metastases at initial referral. The median number of symptoms was slowly progressive ranging from 2 (range 0–5) before
ﬁrst-line chemotherapy (n = 50) to 3 (range 1–6) at the time of best supportive care (BSC) decision (n = 48). Pain and dyspnoea
were the commonest symptoms. Median overall survival from BSC decision was 3.4 weeks. 88% had PC involvement (either
hospital, community, or both) with median time from ﬁrst PC referral to death of 16 (range 0–110) weeks. Conclusions. Patients
with metastatic STS have a signiﬁcant symptom burden which justiﬁes early PC referral. Pain, including neuropathic pain, is a
signiﬁcant problem. Dyspnoea is common, progressive and appears to be undertreated. Time from BSC decision to death is short,
and prospective studies are required to determine whether this is due to overtreatment or very rapid terminal disease progression.
1.Introduction
Soft tissue sarcomas are malignant tumours of connective
tissue comprising over 50 diﬀerent histological subtypes
which vary in their clinical behaviour and response to
treatment [1, 2]. Surgery, often supplemented by adjuvant
radiotherapy, oﬀers the only reliable chance of cure for
localised disease [2, 3]; however, over 50% of soft tissue
sarcoma (STS) patients will develop metastases [4, 5].
Whilst metastasectomy is increasingly possible [6], palliative
treatment generally consists of radiotherapy for locally
advanced “inoperable” recurrence and systemic chemother-
apy for widespread metastatic disease [1–3]. The aim of
such palliative treatments is to establish disease control thus
improving survival and symptomatology [2].
Median overall survival (OS) from commencing ﬁrst-
and second-line palliative chemotherapy is reported as 12
months [7, 8] and 8 months [9], respectively. Systemic
chemotherapy has the potential for signiﬁcant toxicity [10],
and whilst this is routinely recorded as part of clinical
trials [11], there is a paucity of generalised STS symptom
prevalence data. A recent study of the STS population as a
whole in one United Kingdom (UK) sarcoma unit found a
pain prevalence of 53% at the time of assessment of which
63% was described as inadequately controlled [12].
Disease- or treatment-related symptoms are frequently
managed by oncologists; however, more complex symptom
control can be challenging and require specialist input.
Given the potential for symptoms and limited prognosis,
there would seem a clear role for palliative care (PC) team
involvement in the advanced STS population.
Palliative care is deﬁned by the World Health Organisa-
tion (WHO)as“anapproachthatimprovesthequalityoflife
of patients and their families facing the problems associated
withlifethreateningillness,throughthepreventionandrelief
of suﬀering by means of early identiﬁcation and impeccable2 Sarcoma
assessment and treatment of pain and other problems,
physical, psychosocial and spiritual” [13]. PC teams in
the UK provide a spectrum of services including (i) hospital
advice/support teams, (ii) hospices providing admissions
for symptom control, respite, or end of life care, and (iii)
community PC teams who assess and treat patients in their
own homes.
Within UK health care policy, the 2006 National Insti-
tute for health and Clinical Excellence (NICE) guidance
Improving outcomes for people with sarcoma found no speciﬁc
evidence supporting the role of PC teams in patients with
sarcoma [14]. However, it suggested much of its guidance
in the 2004 document improving supportive and palliative
care for adults with cancer [15] was applicable. Speciﬁcally,
this recommends the eﬀectiveness of specialist PC team
involvement for the control of pain and cancer symptoms. It
did not, however, suggest when or if PC referral for symptom
control or holistic support might be appropriate.
Early PC team involvement has been shown to improve
quality of life, mood, and survival in patients with newly
diagnosed metastatic non-small-cell lung cancer, a condition
with a similar prognosis to metastatic STS [16]. However,
in many instances PC is delivered too late to be eﬀective
[17, 18].
There are anecdotal reports by both STS clinicians
and patients that, despite advanced disease, STS patients
maintain a good quality of life with moderate symptoms
until a rapid decline to the ﬁnal weeks [19]. Although there
are no data to support this, the deterioration has been
suggested to diﬀer from the more “predictable” gradual
deterioration experienced by those with other cancers such
as non-small cell-lung cancer [19]. If true, one might expect
that PC team referrals might occur too late to be of beneﬁt
to the STS population. It is important to evaluate symptom
burden and PC input in locally advanced and metastatic
STS to provide recommendations for optimal timing of PC
involvement.
This paper presents the results of a retrospective review
of physical symptoms and PC team involvement in patients
with locally advanced “inoperable”/metastatic STS treated at
one tertiary referral centre in the UK.
The aims were to better deﬁne the number and severity
of physical symptoms at the time of each new treat-
ment decision, for example, before ﬁrst-line chemotherapy,
before second-line chemotherapy, and so forth for locally
advanced/metastatic STS. We also wanted to establish the
most common symptoms in each group, and the proportion
of patients referred to a PC team prior to death along with
their OS from the time of diagnosis with metastatic disease.
2.MaterialsandMethods
The records of all patients with a histological diagnosis of
locally advanced/metastatic STS over the age of 18, known
to the unit and considered for palliative chemotherapy who
died during the 2009 calendar year, were analysed. Patients
were excluded from the analysis if management did not
include palliative chemotherapy assessment (those treated
with surgery or palliative radiotherapy alone), if the STS
unit only provided a treatment opinion and if the death
was considered unrelated to the STS diagnosis. Patients
with Gastro-Intestinal Stromal Tumours (GIST) were also
excluded as in this well-deﬁned subgroup treatment with
molecularly targeted agents such as imatinib can provide a
long-term survival beneﬁt.
Data were collected from the hospital electronic patient
records and a hand search of paper notes. Missing data from
hospital records were obtained from the patient’s primary
care team.
Each patient’s records were analysed from ﬁrst referral
with advanced disease to death. Data collected included
demographic information, tumour-speciﬁc data, treatment
decisions, documented symptoms, and information relating
to PC involvement.
More speciﬁcally, documented physical symptoms were
recorded from the notes prior to each new treatment deci-
sion, for example, before ﬁrst line palliative chemotherapy
and were recorded in four categories; “present controlled”,
“present uncontrolled”, “documented absent”, or “not docu-
mented”.
The term symptom burden can be deﬁned as symptoms
experienced by the patient as a result of the disease itself or
associated treatments [20].
In this study, we assessed clinician documented physical
symptoms prior to the start of a new treatment decision.
The impact of systemic therapy on symptom burden was
not directly studied. Overall survival (OS) was measured
from the start of each new treatment decision until death.
Permission from the clinical audit committee was obtained
prior to data collection.
3. Results
One hundred and forty-two STS patients with locally
advanced/metastatic disease known to the STS unit died
during the review period 1st January 2009–31st December
2009. Sixty-One patients did not meet the inclusion criteria
for review (see Figure 1) resulting in a total of eighty-one
patient records analysed.
3.1. Demographics and Tumour-Speciﬁc Information. The
demographic- and tumour-speciﬁc details of these patients
are described in Table 1. Thirty-ﬁve patients (43%) were
male with a median age at death of 55 years, range from
18 to 84. Seventy-six patients (94%) presented with “new”
advanced “inoperable”/metastatic disease and 5 (6%) had
already received treatment for advanced disease in other
oncology centres prior to review by the STS medical oncol-
ogy unit. Fifty-nine patients (73%) had metastatic disease at
referral, with 17 (29%) having multiorgan disease.
One hundred and ﬁfty-six treatment decisions were
made for the 81 patients and the notes reviewed prior
to each of these decisions. Fifty patients received ﬁrst-line
chemotherapy, 28 second line, 15 third line and 7 fourth line.
Eight patients were referred for phase 1 drug trials, and 48Sarcoma 3
142 patient
deaths 61 patients excluded:
• 23 sarcomas highly sensitive
to systemic treatment e.g,
GISTs
￿ 17 MDT opinion only
￿ 11 treated with palliative
surgery/ radiotherapy only
and not seen by STS medical
oncologists.
￿ 6 non STS related deaths
￿ 3 no STS diagnosis e.g,
benign histology
￿ 1 < 18 years old
81 s
records
included and
reviewed
patient
- -
Figure 1: Proﬁle of patients reviewed.
Table 1: Demographics and tumour-speciﬁc details.
Demographic- and tumour-speciﬁc
factors: Number %
Number: 81
Male 35 43.2
Female 46 56.8
Median age at death (Range) 55 (18–84)
Histology:
Leiomyosarcoma 23 28.4
Liposarcoma 12 14.8
Angiosarcoma 7 8.6
Synovial sarcoma 6 7.4
Sarcoma—(Not other speciﬁed) 6 7.4
Other 27 33.4
Disease status at referral:
Locally advanced/“inoperable” 22 27.2
Metastatic 59 72.8
Metastasis at referral:
Single organ 42 71.2
Multiple organ 17 28.8
Site of metastases at referral:
Lung 38 64.4
Liver 12 20.3
Soft tissue 15 25.4
Bone 9 15.3
Other 9 15.3
patients had a best supportive care (BSC), that is, no further
active treatment decision made by the STS unit.
In addition, seven patients (9%) underwent metastasec-
tomiesafterfavourableresponsestochemotherapy.18(22%)
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Figure 2: Median number of symptoms prior to each treatment
decision.
received palliative radiotherapy at some point after referral
with the documented aims being reduction in primary
tumour size (7 patients), analgesia (5 patients), treatment of
brain metastases (5 patients) and treatment of spinal cord
compression (1 patient).
3.2. Symptom Burden. The median number of symptoms
documented prior to each new treatment decision ranged
from 2 at the time of ﬁrst-line chemotherapy to 3 at BSC
(Figure 2). Table 2 shows all documented symptoms at the
time of each new treatment decision: pain, dyspnoea, and
nausea/vomiting are the three commonest. Other symptoms
include fatigue, constipation, and cough. Both ﬁgures show
thatbeforediﬀerentlinesofchemotherapy,symptomburden
was consistent but increased prior to both decision to refer4 Sarcoma
Table 2:Alldocumentedsymptomspriortodiﬀerentpalliativetreatmentdecisions.(Duetothesmallnumbers,onlydocumentedsymptoms
at the time of ﬁrst- and second-line chemotherapy and best supportive care decision are displayed).
Symptom
First-line palliative
chemotherapy
(n = 50)
Second-line palliative
chemotherapy
(n = 28)
Best supportive care
(n = 48)
Symptom prevalence Symptom prevalence Symptom prevalence
Pain 25 (50%) 23 (82%) 38 (79%)
Breathlessness 10 (20%) 11 (40%) 21 (44%)
Nausea and vomiting 11 (22%) 5 (18%) 17 (35%)
Fatigue 9 (18%) 5 (18%) 16 (33%)
Constipation 6 (12%) 2 (7%) 8 (17%)
Cough 3 (6%) 3 (11%) 9 (19%)
Feeling bloated 9 (18%) 2 (7%) 3 (6%)
Weight loss 6 (12%) 0 (0%) 1 (2%)
Low appetite 4 (8%) 0 (0%) 9 (19%)
Diarrhoea 1 (2%) 0 (0%) 4 (8%)
D r ym o u t h 1( 2 % ) 1( 4 % ) 3( 6 % )
Trouble sleeping 2 (4%) 0 (0%) 4 (8%)
Numbness/tingling in hands/feet 0 (0%) 1 (4%) 3 (6%)
Problems with urination 2 (4%) 0 (0%) 2 (4%)
Sweats 0 (0%) 0 (0%) 1 (2%)
to the Phase 1 trial unit (median 2.5 symptoms) and a best
supportive treatment decision (median 3). The two most
common documented symptoms were pain and dyspnoea.
(a) Pain. Pain was the most common symptom across
all treatment decisions/stages of disease. Fifty percent of
patients starting ﬁrst-line chemotherapy experienced pain;
however, the proportion of patients with pain rose to 82%
(23/28) at second-line chemotherapy and remained similar
at BSC decision (79%, 38/48). Twenty percent (10/50) of
patients were documented as having uncontrolled pain at
ﬁrst-linechemotherapycomparedto48%(23/48)ofpatients
at BSC decision (Table 3). The gold standard for the eﬀective
management of cancer pain is to follow the WHO 3-
step analgesic ladder [21]. Table 4 describes the overall use
of analgesia in these patients. It shows 86% (70/81) of
patients were using a regular “step 1” analgesic, for example,
paracetamolamedianof40weeksbeforedeath,whereas64%
(52/81) required a regular “step 3” analgesic—for example,
a strong opioid, such as oral morphine a median 14 weeks
before death. Interestingly, 28% (23/81) were prescribed
a neuropathic agent such as gabapentin, implying that the
proportion experiencing neuropathic pain was at least 28%.
(b) Dyspnoea. Dyspnoea was the second most common
symptom across all treatment decisions/stages of disease
except at ﬁrst-line chemotherapy. Twenty percent of patients
starting ﬁrst-line chemotherapy experienced dyspnoea; how-
ever, the proportion of patients rose to 39% (11/28) at
second-line chemotherapy, and rose further (44%, 21/48)
at BSC decision (see Table 2). This correlates with lung
being the most common site of STS metastasis. Six percent
(3/50) of patients were documented as having uncontrolled
dyspnoea at ﬁrst-line chemotherapy compared to 31%
(15/48) of patients at BSC decision. Overall, medications
speciﬁcally documented for palliation of dyspnoea (opioids
or benzodiazepines) were prescribed in only 15% (12/81) of
patients, suggesting that this symptom is undertreated.
3.3. Overall Survival. M e d i a nO Sf r o mﬁ r s tr e f e r r a li r r e -
spective of treatment (n = 81) was 38.7 weeks (Table 5)
indicating the relatively poor prognosis of this STS cohort.
The median OS times from start of ﬁrst- and second-line
chemotherapy mirror established data [7–9]. Of the 59%
with a documented BSC decision, OS from decision was 3.4
weeks (range 1–62).
3.4. Palliative Care Team Involvement. 71 patients (88%) had
a PC team referral made either to the hospital team alone
(7/71), a community team alone (26/71), or both (38/71).
The median time before death from ﬁrst PC team referral
was 15.8 weeks (range 0.1–110.3).
4. Discussion
Patients with locally advanced/metastatic STS generally
undergochemotherapytopalliatenotcure.Thispapershows
that these patients experience a signiﬁcant symptom burden
that can be diﬃcult to control. The authors, hope these
symptom prevalence data are generalisable and therefore, of
value to oncologists treating STS.
The median number of documented symptoms ranged
from 2 at ﬁrst-line chemotherapy to 3 at BSC decision
suggesting sustained and slowly progressive symptoms. The
prevalence of documented pain before diﬀerent palliativeSarcoma 5
Table 3: The documentation of symptoms. (Due to the small numbers, only the three commonest documented symptoms at the time of
ﬁrst- and second-line chemotherapy and best supportive care decision are shown here).
Symptom
First-line palliative
chemotherapy
(n = 50)
Second-line palliative
chemotherapy
(n = 28)
Best supportive care
(n = 48)
Pain documented as:
Present controlled 15 (30%) 19 (68%) 15 (31%)
Present uncontrolled 10 (20%) 4 (14%) 23 (48%)
Absent documented 15 (30%) 2 (7%) 7 (15%)
Not recorded 10 (20%) 3 (11%) 3 (6%)
Breathlessness documented as:
Present controlled 7 (14%) 10 (36%) 6 (13%)
Present uncontrolled 3 (6%) 1 (4%) 15 (31%)
Absent documented 20 (40%) 8 (28%) 20 (43%)
Not recorded 20 (40%) 9 (32%) 7 (15%)
Nausea and Vomiting documented as:
Present controlled 8 (16%) 4 (14%) 15 (31%)
Present uncontrolled 3 (6%) 1 (4%) 2 (4%)
Absent documented 21 (42%) 15 (54%) 21 (44%)
Not recorded 18 (36%) 8 (28%) 10 (21%)
Table 4: Symptom control drug use.
WHO Class 1
Analgesic,
for example,
Paracetamol
WHO Class 2
Analgesic,
for example,
Codeine
WHO Class 3
Analgesic,
for example,
Morphine sulphate
Agent speciﬁed for
neuropathic pain,
for example,
Gabapentin
Agent speciﬁed for
dyspnoea,
for example,
Lorazepam
Patients using 70 52 52 23 12
%8 6 6 4 6 4 2 8 1 5
Median time started before
death in weeks (Range)
39.7
(1–202)
32.3
(2–206)
13.9
(1–106)
11.1
(1–83)
3.4
(1–56)
treatment decisions was consistently above 50%. This cor-
relates with a systematic review by van den Beuken-van
Everdingen et al. suggesting pain prevalence to be 64%
in those with advanced/metastatic/terminal cancer of any
type [22]. Furthermore, a recent study investigating pain
prevalence in the STS population as a whole found a
prevalence of 53% [12]o fw h i c h3 6 %w e r ef o u n dt oh a v e
neuropathic pain. Whilst documented interpretation of pain
type was not recorded, 28% of patients in this paper were
prescribed neuropathic analgesic agents correlating with this
recent published data.
Dyspnoea can be multifactorial in aetiology; however,
the high prevalence of documented breathlessness correlates
with lung as the commonest site of metastases in STS.
At referral, 38 of the 59 patients (64%) with metastatic
disease had lung metastases; this is comparable to ﬁndings
from other studies [7, 8, 23]. The increasing prevalence
of dyspnoea through lines of chemotherapy likely reﬂects
disease progression in the lungs. The small number of
patients on a medication speciﬁcally to palliate dyspnoea
(12 patients) may represent clinicians’ lack of conﬁdence in
treating this symptom or a lack of documentation clarifying
why these drugs (e.g., opiates or benzodiazepines) were
prescribed.
OnestrikingstatisticisthatthosewhohadaBSCdecision
(48/81) had a median OS of only 3.4 weeks. This may suggest
“active” treatment is being continued late into the disease
trajectory, against recommendations arising from a national
UK report reviewing deaths within 30 days of receiving
systemic anticancer therapy [24]. Conversely, it may also
add support to the anecdotal observation that STS patients
remain relatively well with good quality of life until late into
theirillnessbeforearapiddeteriorationtowardstheterminal
phase [19].
Importantly, the median OS for all patients was signif-
icantly less than one year. The UK Department of Health
E n do fL i f eC a r eS t r a t e g y[ 25] advocates the importance of
individualised care plans and PC involvement in the last year
of life. Given this policy, all the patients in this paper should
have had some PC involvement. Encouragingly, 88% of
patients were referred to a PC team, with a high proportion
of these (64/71, 90%) known to community PC teams.
Although not reviewed, this may have enabled advanced care
planning such as a patients preferred place of care and death6 Sarcoma
Table 5: Overall survival.
Overall First-line
chemo
Second-line
chemo
Third-line
chemo
Fourth-line
chemo
Phase 1 drug
trial
Best
supportive
care
Number of patients 81 50 28 15 7 8 48
O v e r a l ls u r v i v a li n
weeks (Range)
38.7
(1–212)
48.6
(3–200)
43.0
(1–151)
15.8
(5–100)
13.6
(9–27)
14.9
(1–46)
3.4
(1–62)
to be established and facilitated. The median time from ﬁrst
PC referral to death of 15.8 weeks may suggest patients at
this centre are being referred early enough to potentially
beneﬁt from the PC service. The data also suggest that the
majority of patients experience symptoms earlier, often from
the initial diagnosis of locally advanced/metastatic disease
which, therefore, adds further weight to considering PC
sooner.
There are no guidelines at this centre regarding the
appropriateness or timing of referral to a PC team. Decisions
to refer are made on an individual basis by the oncology
team or general practitioner after patient consultation. A
nationwide survey of American doctors suggested 13 weeks
before death as the most appropriate time to refer to a
hospice care program [26]. However, studies in America and
other countries have shown physicians refer cancer patients
to PC teams/hospice care programs much nearer death—
with median survival from initial referral ranging from 3
to 8 weeks [27–32]. Barriers to early PC referrals include
(i) limitations in PC access between and within countries,
(ii) reluctance of patients/families to be referred because
of misunderstandings of what PC may oﬀer/its perceived
association with imminent death, and (iii) resistance by clin-
icians to refer patients still having “active” treatment/their
reluctance to discuss end of life issues [33–35]. Interestingly,
our data show that 48% (23/48) of patients in this review
had documented uncontrolled pain and 31% (15/48) had
uncontrolled dyspnoea at the time of a BSC decision. Most
had already been referred to a PC team by this point.
This may indicate inadequate access to PC services despite
referral, or that a rapid escalation in “diﬃcult to control”
pain/dyspnoea is a predictive factor for the terminal phase
in STS patients.
The authors recognise these data are from a single UK
cancer center. Results will be indicative of the STS units
individual practice as well as UK health policy which limits
generalisation nationally or globally. Other countries may
have diﬀerent protocols and treatment thresholds which
might inﬂuence results. That said, OS data from ﬁrst- and
second-line chemotherapy were similar to those of larger
cohorts [7–9].
The availability of PC services varies within the UK
[36]andgreatlybetween/withinotherEuropeanandwestern
countries [37–41] reﬂecting the heterogeneity of health care
systems, patient’s needs and cultures. The UK has a relatively
active PC network and its government has recently invested
in PC resources and end of life care [25, 42].
The studies retrospective design is also a potential source
of major bias: the symptom data are based on clinician
documentation where factors such as inadequate assessment,
time pressure, and selective documentation of positive
ﬁndings may all contribute to inaccuracy. Recording symp-
toms prospectively using validated patient reported outcome
measures may lead to more accurate assessment/outcomes
[43]. Patients whose death was not thought attributable to
STS were excluded: this is diﬃcult to establish; therefore, all
deaths should have been analysed.
5. Conclusions
Locally advanced “inoperable”/metastatic STS patients have
a signiﬁcant symptom burden which is slowly progressive
and commonly includes pain and dyspnoea. The level
and timing of PC team referrals in this UK single centre
evaluationwas encouraging. However,pain wasdocumented
as uncontrolled in 48% of patients at the time of ﬁrst-
line chemotherapy and patients had at least two symptoms
at the time of all treatment decisions. There was also a
suggestion that dyspnoea was undertreated. The short time
from documented BSC decision to death is a concern:
this could suggest that patients continue active treatment
too long, or that this is due to extremely rapid disease
progression in the terminal phase.
Given the prevalence of symptoms, potential for treat-
ment toxicity, and poor OS, prospective quality of life data
could aid decision making in the STS population. Given the
potential for PC to improve quality of life and survival in
patients with advanced cancer, these data support the need
for early PC referral in patients with metastatic STS. The lack
of prospective studies into this important area indicates the
need for further research.
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